A Phase 1a Open-Label, Single Ascending Dose Study to Evaluate the Safety and Tolerability of Intravitreally Administered PYC-001 in Participants with Confirmed OPA1 Mutation-Associated Autosomal Dominant Optic Atrophy
Latest Information Update: 05 Feb 2025
At a glance
- Drugs PYC-001 (Primary)
- Indications Optic atrophy
- Focus Adverse reactions; First in man
- Sponsors PYC Therapeutics
- 07 Nov 2024 Status changed from not yet recruiting to recruiting.
- 11 Jun 2024 Status changed from planning to not yet recruiting.
- 01 Nov 2022 New trial record